Unlike general health products stocked in every health store, CJC-1295 is distributed via a global research peptide market that Baja residents reach through online vendors. This matters because CJC-1295 quality ranges widely across the market — from pharmaceutical-grade 99%+ purity to mislabeled or underdosed compounds — and the vendor is the entire quality system. Separating genuine research-grade CJC-1295 from the rest of the market requires three things: an HPLC chromatogram confirming ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to evaluate CJC-1295 vendors rigorously — the framework here work regardless of your location.
What Studies Say About CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Baja comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
Before evaluating any specific vendor, understand what genuine quality documentation contains — so you can recognise whether a vendor meets it. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone provides no identity confirmation. Warning signs in CJC-1295 vendor evaluation: prices significantly below market average, vague sourcing information, no community presence, and COAs that omit endotoxin testing. For Baja researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Baja
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human therapeutic use by the FDA or comparable health authorities — all information here is educational. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and used within 30 days; reconstitute only with bacteriostatic water. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no cost saving makes omitting this acceptable. Researchers combining CJC-1295 with other compounds should examine published studies for potential interaction data before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
